DOES MCDA LEAD TO BETTER PATIENT ACCESS IN AFRICA?


- Dr. Tienie Stander
- Tienie.stander@tcd-global.com
- www.tcd-global.com



- Does <u>MCDA</u> lead to better patient access in Africa?
- Does MCDA lead to <u>better patient</u> access in Africa?
- Does MCDA lead to better patient access in Africa?

MCDA


- Using MCDA in which application:
 - · Risk-benefit assessment used by Regulators?
 - Health Technology Assessment by agencies?
 - Priority setting by local budget holders?
- · Which model?
 - EUnetHTA HTA Core Model
 - (https://www.eunethta.eu/hta-core-model/)
- Which criteria?
 - EVIDEM
 - (https://www.evidem.org/wp/wpcontent/uploads/2017/09/EVIDEM-10th-Edition-Evidence-matrix.pdf)





Patient Access

- Access to what?
- Orphan drugs
- · Oncology drugs
- · Communicable disease treatments
- Non-communicable disease treatments
- · Innovative medicines and technology?



Africa

- Ghana¹
- South Africa²
- 1. Jehu-Appiah C, Baltussen R, Acquah C, et al. Balancing equity and efficiency in health priorities in Ghana: the use of multicriteria decision analysis. Value Health. 2008;11(7):1081–1087.
- 2. Miot J, Wagner M, Khoury H, et al. Field testing of a multicriteria decision analysis (MCDA) framework for coverage of a screening test for cervical cancer in South Africa. Cost Eff Resour Alloc. 2012 Feb 29;10(1):2)

http://www.redcriteria.org/en/wp-content/uploads/2015/07/Marsh_14_Pharmaco_MDCA.pdf

Conclusion

- MCDA appears to be a step in the right direction
- In isolation it will not lead to better patient access
- Challenges in low-resource settings are beyond MCDA
- Socioeconomic issues such as education, sanitation, water, unemployment, primary care will drive health outcomes
- · Consider opportunity costs
- Think healthcare ECOSYSTEM in Africa
- Think <u>VALUECHAIN</u>

